CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Lopinavir/Ritonavirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00038480
NCT00038480Phase 1Completed
CompareCT.gov

A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jun 3, 2002·Updated Nov 1, 2021

In Brief

A Phase 1 clinical trial evaluating Lopinavir/Ritonavir for HIV Infections. Completed, enrolled 31 participants across 17 sites in 3 countries.

Detailed Summary

The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe and well tolerated in HIV infected infants. This study will also determine the most effective dose of LPV/RTV for infants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesBrazil, Puerto Rico, United States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2002
Study CompletionSep 1, 2007
TodayJul 2, 2026
Posted 24.1 years ago

Interventions

Lopinavir/Ritonavirdrug